A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices: The Novel Cor-IS Technology Will Also be Evaluated
Launched by ARISTOTLE UNIVERSITY OF THESSALONIKI · Mar 20, 2025
Trial Information
Current as of May 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to better understand how a specific test called flow mediated dilation (FMD) can help predict outcomes for patients experiencing acute coronary syndromes, which are serious heart conditions like heart attacks. The study will also look at other heart tests and new technology to gather more information. Researchers aim to see if these tools can help doctors make better decisions about treatment.
To join this study, participants need to be at least 18 years old and hospitalized due to acute coronary syndrome. This includes conditions like STEMI or NSTEMI heart attacks. However, certain patients are not eligible, such as those over 85 years old or with specific heart issues or serious health problems. If someone qualifies and decides to participate, they can expect to provide consent and follow a schedule for check-ups during the study. This research is currently active but not looking for new participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 18 years
- • 2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)
- • 3. Capability of providing written informed consent
- • 4. Patients able to comply with the follow-up schedule of the study
- Exclusion Criteria:
- • 1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction
- • 2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome
- • 3. Patients with congenital heart disease
- • 4. Age \> 85 years
- • 5. Patients with end stage chronic kidney disease
- • 6. Patients with active malignancy or autoimmune diseases which limit their survival
- • 7. Patients with expected survival \< 1 year due to other reasons
- • 8. Suboptimal echocardiographic windows
- • 9. Inability to provide written consent
- • 10. Inability to comply with the follow-up schedule of the study
- • 11. Pregnancy
- • 12. Use of intravenous drugs
About Aristotle University Of Thessaloniki
Aristotle University of Thessaloniki (AUTH) is a prestigious institution in Greece, renowned for its commitment to advancing knowledge and innovation in the field of clinical research. As a leading academic sponsor of clinical trials, AUTH leverages its extensive resources and expertise to conduct rigorous studies that contribute to the understanding of various medical conditions and the development of novel therapeutic interventions. The university fosters collaboration among multidisciplinary teams, ensuring adherence to the highest ethical standards and regulatory requirements while promoting scientific excellence and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, , Greece
Patients applied
Trial Officials
Christodoulos E. Papadopoulos, PhD
Principal Investigator
Aristotle University of Thessaloniki, Greece
Georgios Zormpas, MD
Principal Investigator
Aristotle University of Thessaloniki, Greece
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported